Pembrolizumab + Enfortumab Vedotin
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urinary Bladder Cancer, Muscle-invasive
Conditions
Urinary Bladder Cancer, Muscle-invasive
Trial Timeline
Jul 24, 2019 → Dec 15, 2027
NCT ID
NCT03924895About Pembrolizumab + Enfortumab Vedotin
Pembrolizumab + Enfortumab Vedotin is a phase 3 stage product being developed by Astellas Pharma for Urinary Bladder Cancer, Muscle-invasive. The current trial status is active. This product is registered under clinical trial identifier NCT03924895. Target conditions include Urinary Bladder Cancer, Muscle-invasive.
What happened to similar drugs?
20 of 20 similar drugs in Urinary Bladder Cancer, Muscle-invasive were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03924895 | Phase 3 | Active |
Competing Products
20 competing products in Urinary Bladder Cancer, Muscle-invasive